Education
About Us
Working with TipRanks
Follow Us
Achieve Life Sciences Inc (ACHV)
NASDAQ:ACHV
ACHV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.82 - $5.59
Previous CloseN/A
Volume131.37K
Average Volume (3M)200.99K
Market Cap
$100.42M
Enterprise Value$129.78M
Total Cash (Recent Filing)$9.52M
Total Debt (Recent Filing)$23.00K
Price to Earnings (P/E)―
Beta1.34
Next Earnings
May 08, 2025EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.13
Shares Outstanding34,685,074
10 Day Avg. Volume163,840
30 Day Avg. Volume200,991
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.50
P/FCF Ratio0.00
Enterprise Value/Market Cap1.29
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-4.33
Forecast
1Y Price Target
$13.00Price Target Upside345.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Achieve Life Sciences News
PremiumCompany Announcements
Achieve Life Sciences: Cautious Optimism in Earnings Call
PremiumCompany Announcements
Achieve Life Sciences Reports 2024 Financial Results
PremiumCompany Announcements
Achieve Life Sciences Announces Board of Directors Changes---
Bulls Say, Bears Say
Bulls Say
Financial PositionACHV ended 3Q24 with a cash position of $42.9 million, which the company estimates will be sufficient to fund operations into 2H25.
Regulatory ApprovalFavorable end-of-Phase II meeting with the FDA clears the path for a significant vaping cessation opportunity.
Bears Say
Market PerceptionThe market is believed to be dramatically underestimating the commercial potential of cytisinicline, reinforcing the Buy rating and $20 price target.
---
Ownership Overview
10.47% Insiders
14.43% Mutual Funds
16.07% Other Institutional Investors
49.76% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ACHV FAQ
What was Achieve Life Sciences Inc’s price range in the past 12 months?
Achieve Life Sciences Inc lowest stock price was $2.81 and its highest was $5.59 in the past 12 months.
What is Achieve Life Sciences Inc’s market cap?
Achieve Life Sciences Inc’s market cap is $100.42M.
When is Achieve Life Sciences Inc’s upcoming earnings report date?
Achieve Life Sciences Inc’s upcoming earnings report date is May 08, 2025 which is in 56 days.
How were Achieve Life Sciences Inc’s earnings last quarter?
Achieve Life Sciences Inc released its earnings results on Mar 11, 2025. The company reported -$0.36 earnings per share for the quarter, missing the consensus estimate of -$0.341 by -$0.019.
Is Achieve Life Sciences Inc overvalued?
According to Wall Street analysts Achieve Life Sciences Inc’s price is currently Undervalued.
Does Achieve Life Sciences Inc pay dividends?
Achieve Life Sciences Inc does not currently pay dividends.
What is Achieve Life Sciences Inc’s EPS estimate?
Achieve Life Sciences Inc’s EPS estimate is -0.38.
How many shares outstanding does Achieve Life Sciences Inc have?
Achieve Life Sciences Inc has 34,685,074 shares outstanding.
What happened to Achieve Life Sciences Inc’s price movement after its last earnings report?
Achieve Life Sciences Inc reported an EPS of -$0.36 in its last earnings report, missing expectations of -$0.341. Following the earnings report the stock price went down -4.575%.
Which hedge fund is a major shareholder of Achieve Life Sciences Inc?
Currently, no hedge funds are holding shares in ACHV
---
Achieve Life Sciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.00 (345.21% Upside)
$13.00 (345.21% Upside)
Blogger Sentiment
Bullish
ACHV Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.1%
Last 30 Days ▼ 5.4%
Last 30 Days ▼ 5.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.87%
12-Months-Change
Fundamentals
Return on Equity
-186.03%
Trailing 12-Months
Asset Growth
96.89%
Trailing 12-Months
Company Description
Achieve Life Sciences Inc
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products, cytisine, is a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.
---
ACHV Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a company on the cusp of significant milestones with the upcoming NDA submission for cytisinicline, highlighting strong progress in clinical trials and financial health. However, challenges remain, particularly in securing financing for future vaping cessation trials and managing high operating expenses. The overall sentiment is cautiously optimistic, with substantial achievements in place but significant dependencies on future regulatory approvals.Read More>---
ACHV Stock 12 Month Forecast
Average Price Target
$13.00
▲(345.21% Upside)
Technical Analysis
Best Analysts Covering ACHV
1 Year
1 Year Success Rate
6/13 ratings generated profit
1 Year Average Return
-0.75%
reiterated a buy rating 2 months ago
Copying Francois Brisebois's trades and holding each position for 1 Year would result in 46.15% of your transactions generating a profit, with an average return of -0.75% per trade.
---